Is an antithrombotic strategy after transcatheter aortic valve implantation clearer now?

J Thromb Thrombolysis. 2021 Nov;52(4):1160-1164. doi: 10.1007/s11239-021-02473-9. Epub 2021 May 24.

Authors

Meina Lv^{1

2}, Shaojun Jiang^{1

2}, Tingting Wu^{1

2}, Wenjun Chen^{1

2}, Jinhua Zhang^{3

4}

Affiliations

¹ Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, 350001, China.
² College of Pharmacy, Fujian Medical University, Fuzhou, 350108, China.
³ Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, 350001, China. pollyzhang2006@126.com.
⁴ College of Pharmacy, Fujian Medical University, Fuzhou, 350108, China. pollyzhang2006@126.com.

PMID: 34028670
DOI: 10.1007/s11239-021-02473-9

No abstract available

Publication types

Letter

MeSH terms

Aortic Valve / surgery
Aortic Valve Stenosis* / surgery
Fibrinolytic Agents / therapeutic use
Humans
Transcatheter Aortic Valve Replacement* / adverse effects

Substances

Fibrinolytic Agents

Grants and funding

2019-CX-19/Fujian Medical Innovation Project of China